九州通：关于子公司盐酸倍他司汀片上市申请收到国家药品监督管理局《受理通知书》的公告

Core Viewpoint - The announcement indicates that the company’s subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., has received the acceptance notice for the marketing application of Betahistine Dihydrochloride Tablets from the National Medical Products Administration, which is a significant step towards product commercialization [2] Group 1 - The marketing application acceptance notice was issued on February 5, 2026 [2] - The product in question is Betahistine Dihydrochloride Tablets, which may have implications for the company's product portfolio and market strategy [2]